Monthly Archives: September 2026


What if clues to longer, healthier lives are hidden in bat DNA?





A new study published in Nature has identified genetic patterns in long-lived Myotis bats that could help scientists better understand the relationship between longevity, immunity, DNA damage and disease resistance. Researchers analyzed the genomes of eight Myotis species and found that genes associated with longer lifespans substantially overlap with genes involved in interactions with viruses.





The research was led by Juan M. Vazquez, with Peter H. Sudmant, M. Elise Lauterbur, Lucie Etienne and David Enard among the scientists who jointly supervised the work. The international research team included scientists from the University of California, Berkeley; University of Arizona; University of Vermont; École Normale Supérieure de Lyon; Université de Strasbourg; University of Michigan and other institutions.





The researchers also examined cells obtained from bat wing biopsies. In the longest-lived species studied, the little brown bat (Myotis lucifugus), severely damaged cells showed increased activity in genes associated with cell death, rather than primarily activating DNA-repair mechanisms.





This suggests that some long-lived animals may protect themselves not only by repairing damaged cells, but also by efficiently eliminating cells that have become too damaged to safely recover. Similar cellular strategies have been observed in other long-lived, cancer-resistant animals, including elephants.





Longevity and viral defense





Another important finding was the overlap between genes associated with longevity and genes involved in interactions with viruses.





The researchers found that Myotis bats have undergone strong evolutionary selection in genes associated with DNA viruses. Their findings add to growing evidence that the evolution of immune defenses, viral interactions and mechanisms for maintaining cellular health may be closely connected.





The study does not mean that scientists have discovered a way to extend human lifespan. Instead, it provides another example of how comparative genomics can reveal biological strategies that may eventually help researchers understand human aging and disease.





For African genomics and biotechnology, the research also highlights the value of studying the genetic diversity of different species. Understanding how organisms naturally adapt to disease, environmental pressures and cellular damage can generate new questions for biomedical research.





MyAfroDNA connects research with the molecular tools that make discoveries like these possible. From DNA isolation and PCR to sequencing and molecular testing, reliable laboratory workflows are essential for studying biological samples and generating genomic data.





Interested in molecular testing or sequencing for your research project? Contact MyAfroDNA to learn more about our services.





Source: University of California, Berkeley / Nature
Research paper: Insights into longevity and virus-driven adaptation from Myotis bat genomes
DOI: 10.1038/s41586-026-10932-7







Could CAR-T therapy be engineered directly inside the human body? New findings reported in Nature suggest that this approach may be possible—and could eventually transform how certain autoimmune diseases are treated.CAR-T cell therapy has traditionally involved removing a patient's T cells, genetically modifying them in a laboratory to recognize specific disease-causing cells, and then infusing the engineered cells back into the patient. While this approach has produced remarkable results in some blood cancers, it can be complex, expensive and time-consuming.





Now, researchers are exploring a different strategy: making the therapeutic CAR-T cells inside the patient's body.In a small clinical trial involving 16 people with multiple sclerosis and other autoimmune conditions, researchers used a modified lentivirus to deliver genetic instructions directly to immune cells. These instructions enabled the participants' T cells to produce chimeric antigen receptors (CARs), allowing them to target B cells associated with the production of harmful autoantibodies.Following treatment, researchers observed an increase in CAR-T cells alongside reductions in B cells and autoantibodies. Participants with multiple sclerosis also experienced improvements in motor and cognitive function and reductions in fatigue, while participants with other autoimmune conditions showed improvements in muscle strength and inflammation.The findings are encouraging, but they are not yet proof that the treatment is effective or provides a permanent reset of the immune system. The trial was small, and participants were followed for approximately six months. Larger studies and longer follow-up will be necessary to establish the treatment's safety, effectiveness and durability.If successful, in-vivo CAR-T therapy could represent an important evolution in cell and gene therapy. Instead of manufacturing therapeutic cells outside the body, biotechnology could potentially provide the genetic instructions needed for the patient's own immune system to produce them.For researchers and the wider biotechnology sector, this development demonstrates how advances in gene delivery, immunology and molecular biotechnology are opening new possibilities for treating complex diseases.





At MyAfroDNA, we are committed to advancing biotechnology and supporting scientific research through molecular testing, DNA and RNA services, sequencing, species identification, paternity testing, molecular diagnostics and access to African biospecimens.Read the original report in Nature for more on this emerging approach to CAR-T therapy.